Madrigal Pharmaceuticals Kicks Off Phase 3 Trial for Rezdiffra in Compensated MASH Cirrhosis
Madrigal Pharmaceuticals has granted equity awards to 27 new non-executive employees. The awards are part of their inducement package, offering options to purchase 1,602 shares and 10,973 time-based restricted stock units. The exercise price is set at $449.14 per share.
Madrigal Pharmaceuticals, a biopharmaceutical company specialising in MASH treatments, has kicked off a Phase 3 clinical trial for Rezdiffra, its drug for compensated cirrhosis. The trial began around the time of Rezdiffra's FDA approval in March 2024 for MASH with moderate to advanced fibrosis. Since then, regulatory progress has continued, including an EMA conditional approval recommendation in June 2025.
Rezdiffra, a once-daily, oral, liver-directed THR-β agonist, targets key underlying causes of cirrhosis. It is already approved for MASH with moderate to advanced fibrosis (F2 to F3) by both the FDA and European Commission. An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated cirrhosis (F4c).
Madrigal Pharmaceuticals' equity awards to new employees reflect the company's growth and commitment to its cirrhosis-focused pipeline. The Phase 3 trial for Rezdiffra in compensated cirrhosis is progressing, with positive regulatory developments to date.
Read also:
- Inadequate supply of accessible housing overlooks London's disabled community
- Strange discovery in EU: Rabbits found with unusual appendages resembling tentacles on their heads
- Duration of a Travelling Blood Clot: Time Scale Explained
- Fainting versus Seizures: Overlaps, Distinctions, and Proper Responses
